Based on 4Q13 US Copaxone sales of $805M (#msg-96917776), the commentary in #msg-90394447 on the long-term outlook of Copaxone in the US market remains valid, IMO.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”